Beam Therapeutics enters $1.35B collaboration with Pfizer for in vivo base editing programs

Beam Therapeutics Inc.

Exclusive 4-year collaboration with Pfizer on 3 rare disease targets (liver, muscle, CNS).
$300M upfront; eligible for up to $1.35B milestones plus royalties.
Preliminary cash: ~$0.9B actual, $1.2B pro forma including $300M upfront.
First subject enrollment in BEAM-101 Phase 1/2 trial for sickle cell disease expected H2 2022.
BEAM-301 (GSDIa) named fourth dev candidate; IND-enabling studies planned in 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.